Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Migraine Disorders, Date of authorisation: 24/01/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Leqvio, inclisiran, Hypercholesterolemia;Dyslipidemias, Date of authorisation: 09/12/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Posaconazole AHCL, posaconazole, Mycoses, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Narcolepsy, Date of authorisation: 31/03/2016, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 22/07/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Date of authorisation: 22/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Leukemia, Myeloid, Acute, Date of authorisation: 19/04/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Osteoporosis;Osteoporosis, Postmenopausal, Date of authorisation: 12/01/2023, Revision: 1, Status: Authorised

PRAC recommendations on signals for update of the product information adopted at the 23-26 October 2023 PRAC

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Spondylitis, Ankylosing;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Psoriasis;Arthritis, Rheumatoid, Date of authorisation: 02/02/2000, Revision: 72, Status: Authorised